185 related articles for article (PubMed ID: 16476042)
21. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
22. Periodontal assessment of postmenopausal women receiving risedronate.
Palomo L; Bissada NF; Liu J
Menopause; 2005; 12(6):685-90. PubMed ID: 16278611
[TBL] [Abstract][Full Text] [Related]
23. Assessment of DNA damage in postmenopausal women under osteoporosis therapy.
Bayram M; Soyer C; Kadioglu E; Sardas S
Eur J Obstet Gynecol Reprod Biol; 2006 Aug; 127(2):227-30. PubMed ID: 16504368
[TBL] [Abstract][Full Text] [Related]
24. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
Greenspan SL; Resnick NM; Parker RA
JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324
[TBL] [Abstract][Full Text] [Related]
27. Levels of matrix metalloproteinases-8 and -9 with simultaneous presence of periodontal pathogens in gingival crevicular fluid as well as matrix metalloproteinase-9 and cholesterol in blood.
Söder B; Airila Månsson S; Söder PO; Kari K; Meurman J
J Periodontal Res; 2006 Oct; 41(5):411-7. PubMed ID: 16953818
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
29. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
[TBL] [Abstract][Full Text] [Related]
30. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP
Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490
[TBL] [Abstract][Full Text] [Related]
31. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
32. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
33. Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women.
Ylikorkala O; Eviö S; Välimäki M; Tiitinen A
Fertil Steril; 2003 Sep; 80(3):541-5. PubMed ID: 12969695
[TBL] [Abstract][Full Text] [Related]
34. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
[TBL] [Abstract][Full Text] [Related]
35. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
38. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
39. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis.
Maugeri D; Mamazza C; Lo Giudice F; Puglisi N; Muscoso EG; Rizzotto M; Testaì M; Bennati E; Lentini A; Panebianco P
Arch Gerontol Geriatr; 2005; 40(3):299-305. PubMed ID: 15814163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
